°ñ´Ù°øÁõÀÌ ÀÖ´Â ³ëÀÎȯÀÚ¿¡¼ÀÇ Ä¡°ú Ä¡·á½Ã °í·Á»çÇ×
Dental considerations for osteoporotic patients
¹Ú¿ø¼, ±èÀ±¹Ì, Á¤º¹¿µ, ¹æ³½É, µµ·¹¹Ì, ±è±â´ö,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¿ø¼ ( Park Won-Se ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ÅëÇÕÁø·áÇаú
±èÀ±¹Ì ( Kim Yun-Mi ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ÅëÇÕÁø·áÇаú
Á¤º¹¿µ ( Jung Bock-Young ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ÅëÇÕÁø·áÇаú
¹æ³½É ( Pang Nan-Sim ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ÅëÇÕÁø·áÇаú
µµ·¹¹Ì ( Doh Re-Mee ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ÅëÇÕÁø·áÇаú
±è±â´ö ( Kim Ki-Deok ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ÅëÇÕÁø·áÇаú
KMID : 1033920090060010006
Abstract
Osteoporosis is very common endocrinologic disease in elderly women. Compression fracture of spine or hip bone is the most severe complication of osteoporosis. Recently, bisphosphonate groups are used for the treatment of osteoporosis, multiple myeloma and metastatic bone disease and these drugs are known as very effective drugs. However, bisphosphonate-related osteonecrosis of the jaw (BRONJ) is on an increasing issue. In this report, we will review the pathophysiology of osteoporosis, effects of bisphosphonate, BRONJ, and dental considerations for osteoporotic patients and under bisphosphonate therapy.
Å°¿öµå
osteoporosis; bisphosphonate; osteonecrosis; jaw
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸